Protalix BioTherapeutics (PLX) Total Liabilities (2010 - 2026)

Protalix BioTherapeutics has reported Total Liabilities for 17 years, with the latest figure at $35.1 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 22.39% year-over-year to $35.1 million; the trailing twelve-month figure through Mar 2026 stood at $35.1 million (up 22.39% YoY), and the FY2025 full-year result was $34.1 million, up 12.94% from the prior year.
• Total Liabilities for Q1 2026 stood at $35.1 million, up from $34.1 million in the prior quarter.
• The five-year high for Total Liabilities was $75.9 million in Q1 2022, with the low at $28.6 million in Q2 2025.
• Average Total Liabilities over 5 years is $49.1 million, with a median of $49.4 million recorded in 2023.
• Year-over-year, Total Liabilities rose 27.41% in 2024 and sank 54.6% in 2025.
• Tracing PLX's Total Liabilities over 5 years: stood at $66.4 million in 2022, then dropped by 23.43% to $50.9 million in 2023, then tumbled by 40.62% to $30.2 million in 2024, then climbed by 12.94% to $34.1 million in 2025, then gained by 2.9% to $35.1 million in 2026.
• The last three Total Liabilities figures came in at $35.1 million (Q1 2026), $34.1 million (Q4 2025), and $29.4 million (Q3 2025), per Business Quant data.

Peer Comparison